• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

by | Apr 24, 2024 | Uncategorized

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma. Read More

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

by | Apr 22, 2024 | Uncategorized

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy. Read More

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

by | Apr 22, 2024 | Uncategorized

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy. Read More

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

by | Apr 22, 2024 | Uncategorized

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma. Read More

Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma

by | Apr 19, 2024 | Uncategorized

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma. Read More

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

by | Apr 18, 2024 | Uncategorized

Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
  • Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
  • Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
  • Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
  • Daratumumab regimen improves survival in transplant-ineligible multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT